首页> 外文期刊>Mini reviews in medicinal chemistry >Targeting of Th1-Associated Chemokine Receptors CXCR3 and CCR5 as Therapeutic Strategy for Inflammatory Diseases
【24h】

Targeting of Th1-Associated Chemokine Receptors CXCR3 and CCR5 as Therapeutic Strategy for Inflammatory Diseases

机译:靶向Th1相关趋化因子受体CXCR3和CCR5作为炎症性疾病的治疗策略

获取原文
获取原文并翻译 | 示例
           

摘要

CXCR3 and CCR5 are chemokine receptor that are predominantly expressed on the surface of Thl polarized T cells. In a variety of human and experimental autoimmune diseases the enhanced expression of CXCR3 and CCR5 binding chemokine ligands is followed by the recruitment of CXCR3- and CCR5-positive T cells, indicating an important role for these chemokine receptors in T cell-mediated tissue damage. In this review, we summarize a number of in vivo studies available on the neutralization of CXCR3 and CCR5 in inflammatory disease, and specifically focus on the potential therapeutic effects of CXCR3 and CCR5 blockade in human autoimmune disease and organ transplantation.
机译:CXCR3和CCR5是趋化因子受体,主要在Th1极化的T细胞表面表达。在多种人类和实验性自身免疫性疾病中,增强CXCR3和CCR5结合趋化因子配体的表达后,会募集CXCR3-和CCR5阳性T细胞,这表明这些趋化因子受体在T细胞介导的组织损伤中具有重要作用。在这篇综述中,我们总结了在炎症性疾病中中和CXCR3和CCR5的许多体内研究,特别是针对CXCR3和CCR5阻断在人类自身免疫性疾病和器官移植中的潜在治疗作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号